Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofazimine Inhalation Suspension in MAC Lung Disease
NCT06418711Phase 3Terminated
- Sponsor
- MannKind
- Start
- Sep 2024
- Primary completion
- Nov 2025
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in Mycobacterium avium complex lung disease comparing Clofazimine Inhalation Suspension with Placebo (2 arms). Primary endpoints: Sputum Culture Conversion at 6 months and Quality of Life-Bronchiectasis Respiratory Symptoms Score at 6 months. Started Sep 2024; status: terminated.
02
Drugs
MNKD-101
03
Conditions
Mycobacterium avium complex lung disease
Beyond the preview
Go deeper on NCT06418711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06418711.